Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection

Schoemaker, Nadja E.; Rosing, Hilde; Jansen, Sindy; Schöffski, Patrick; Rizzo, Jinee; Schellens, Jan H.M.; Beijnen, Jos H.

doi:10.1016/s1570-0232(02)00294-5

Cited by 8 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the HPLC methods developed by Schoemaker et al [24] and Zhong et al [25] only the total form of 9-NC (lactone plus carboxylate) is analysed. Long time procedure of sample preparation and need of laborious solid-phase or liquid-liquid extraction techniques are other disadvantages of these reported methods [24,25].…”

Section: Resultsmentioning

confidence: 99%

“…A few methods, which have been reported for the determination of 9-NC in plasma, analyze the drug only as the total (lactone plus carboxylate) form [24,25]. Since lactone moiety is the active form of this anticancer agent, it is important to design a sensitive analysis method for measurement of both lactone (9NC-lac) and total (9NC-tot) forms in plasma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma

Derakhshandeh

Dadashzadeh

2005

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma

Derakhshandeh

Dadashzadeh

2005

Journal of Chromatography B

View full text Add to dashboard Cite

“…For quantitation of 9-NC in human plasma, previous HPLC-based methods used a simple and straight forward assay involving ultraviolet detection [15] and a chemical method that reduces 9-NC to 9-AC, a fluorescent derivative. The chemical conversion was based on reduction of 9-NC using metallic organic iron (pentacarbonyl) and hydrochloric acid [5].…”

Section: Resultsmentioning

confidence: 99%

Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma

Gounder

Sun

Sands

et al. 2004

Journal of Chromatography B

View full text Add to dashboard Cite

“…Additional blood samples were collected on days 4 and 5 for determination of etoposide pharmacokinetics. Plasma samples were analyzed for 9-NC concentrations by an adaptation of the method previously validated for the high-performance liquid chromatography determination of 9-aminocamptothecin (25).…”

Section: Pharmacokinetic Analysesmentioning

confidence: 99%

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial

Simon¹,

Lush²,

Gump³

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Purpose: Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II inhibitors may result from induction of topo II by topo I inhibitors. Here, we evaluated a sequence-specific administration of a topo I inhibitor followed by a topo II inhibitor. Experimental Design: Twenty-five patients with advanced or metastatic malignancies were treated with increasing doses (0.75, 1.0, 1.25, 1.5, 1.75, or 2.0 mg/m 2 ) of 9-nitrocamptothecin (9-NC) on days 1 to 3, followed by etoposide (100 or 150 mg/d) on days 4 and 5. At the maximally tolerated dose, 20 additional patients were enrolled. The median age was 60 years (range, 40 -84 years). Endpoints included pharmacokinetic analyses of 9-NC and etoposide, and treatment-induced modulations of topo I and II expression in peripheral blood mononuclear cells. Results: Neutropenia, thrombocytopenia, nausea, vomiting, diarrhea, and fatigue were dose-limiting toxicities and occurred in six patients. Despite a median number of four prior regimens (range 1 -12), 2 (4%) patients had an objective response and 13 (29%) patients had stable disease. In contrast to the expected modulation in topo I and IIA levels, we observed a decrease in topo IIA levels, whereas topo I levels were not significantly altered by 9-NC treatment. Conclusions: Sequence-specific administration of 9-NC and etoposide is tolerable and active. However, peripheral blood mononuclear cells may not be a predictive biological surrogate for drug-induced modulation of topo levels in tumor tissues and should be further explored in larger studies.

show abstract

Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection

Cited by 8 publications

References 13 publications

Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma

Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma

Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial

Contact Info

Product

Resources

About